From Months to Minutes: Rewiring Drug Engineering with Al. EMLy Co-pilot Webinar: 12th May 2026 – 9am BST & 4pm BST

This joint study brought together Etcembly’s AI‑designed multi‑specific T cell engagers and Avigen’s cutting‑edge microfluidic avidity platform. It's success marks another step forward in validating AI‑engineered biologics under dynamic, live‑cell conditions.

Building on the success of our previous work together on the MAGE‑A4 TCR — which now underpins ZI‑MA4‑1 and has recently received MHRA approval to enter the clinic — this new partnering between Etcembly and Zelluna focuses on engineering next‑generation KKLC1‑targeting TCRs using our AI‑driven EMLy™ platform.

In this powerful episode of The Futurist, host Ian Khan talks with Michelle Teng on how cancer research is being redefined with the use of artificial intelligence.

See how EMLy Co-Pilot is making biologics discovery faster, smarter and open to all. Read more in Endpoints News.

Imagine discovering new biologics not in weeks, but in minutes...

British techbio innovator Etcembly is recruiting people aged over 18 in the Oxfordshire area who are either healthy, are living with or have survived cancer to participate in their groundbreaking ETCh study aiming to uncover clues to new cancer treatments in their immune cells.

British techbio innovator Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics.

We're delighted to announce a new partnership with leading antibody manufacturer Vector Laboratories, Inc

Docking Run Interpretation and Annotation Tool (DoRIAT) emerges as a standout innovation

We are delighted that our generative AI platform EMLy™️ has been shortlisted as a finalist in the Fierce Innovation Awards 2024

British techbio innovator Etcembly is teaming up with researchers and clinicians from the University of Surrey to launch a groundbreaking...

British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies

Read the full story about top techbio companies here:

Etcembly launching groundbreaking study to uncover whether cancer survivors hold the key to new cures

Marc Emmer at Inc. highlights how our approach could accelerate the development of new immunotherapies. https://www.inc.com/marc-emmer/could-ai-help-cure-cancer.html

Etcembly are showcased as one of the companies driving the UK's AI revolution.

Etcembly co-founder Michelle Teng talks to Helen Albert about her journey in science

Discover how we're enabling our former intern Gusztav Milotay to pursue a PhD at the University of Oxford. https://www.harwellcampus.com/supporting-the-next-generation-in-biotech/

Caroline Richards, BioWorld explores how our AI-driven approach is enabling TCR discovery and optimisation at unprecedented scale and speed